IVI-Biological E. Limited OCV-S Technology Transfer


IVI will transfer oral cholera vaccine technology and know-how to Biological E. Limited.

view more

Credit: IVI

  • IVI plans to complete technology transfer by 2025
  • Oral cholera vaccine, manufactured by Biological E. Limited for Indian and international markets

march 202024, Seoul, Republic of Korea and Hyderabad, India — The International Vaccine Institute (IVI), an international organization with a mission to discover, develop and provide safe, effective and affordable vaccines for global health, today announced that the Convenient Oral Cholera Vaccine (OCV-) technology We announced that we have started relocation. S) has been transferred to Biological E. Limited (BE), a leading India-based vaccine and pharmaceutical company.

After entering into a technology license agreement last November, IVI has begun providing technical information, know-how and materials to manufacture OCV-S at its BE facility and will continue to pursue the necessary clinical development and regulatory approvals. We will support you. IVI and BE enter into this partnership in the midst of an unprecedented surge in cholera outbreaks around the world, with the aim of increasing the amount of low-cost cholera vaccines in public markets in India and globally. Masu.

IVI will complete the technology transfer by 2025 and the oral cholera vaccine will be manufactured by Biological E. Limited for the Indian and international markets.

Dr. Jerome Kim, IVI Executive Director, said:: “At a time of heightened risk of poverty-related infectious diseases such as cholera, the world needs sustainable sources of high-quality, affordable vaccines and dedicated manufacturers to supply them. To address this supply shortage and protect communities from this deadly but preventable disease, we are partnering with Biological E. We are pleased to partner with the company.”

Ms. Mahima Datra, Managing Director, Biological E. Limited said,: “We are delighted to be collaborating with IVI on the production of a simplified oral cholera vaccine. Our efforts aim not only to fight the disease, but also to be part of a lasting legacy of innovation, collaboration and health care. We are pleased to work with IVI to help shape a healthier and more resilient future by making this vaccine available around the world.”

This technology transfer and licensing agreement is IVI's sixth and will transfer such technology to manufacturers in India, South Korea, Bangladesh and South Africa. All these partnerships have led to, or aimed at obtaining, pre-qualification (PQ) from the World Health Organization, which allows global agencies such as UNICEF to procure vaccines for the global market. BE already has nine vaccines in its portfolio, including WHO PQ, and IVI and BE will also pursue WHO PQ for OCV-S, subject to national approval in India.

Dr Julia Lynch, IVI Cholera Program Director, said:: “The cholera situation is dire, and the availability and use of oral cholera vaccines is an important part of a multipronged approach to cholera control and prevention, especially as epidemics increase and global vaccine supplies remain tight.” With manufacturers like BE entering the market, the future supply situation looks solid. We remain committed to developing new and improved vaccines for the world that are affordable and manufactured globally.”

OCV-S is a simplified formulation of OCV that has the potential to reduce production costs while increasing production capacity for current and aspiring OCV manufacturers. IVI's development and ongoing technology transfer of his OCV-S is aimed at achieving his three main goals: 1) securing the supply of OCV, 2) improving the cholera vaccine, and 3) supporting the use and introduction of OCV. It is part of an organized strategy to combat cholera. The Bill & Melinda Gates Foundation has supported IVI's cholera program since 2000 and is funding the latest technology transfers to BE.


about International Vaccine Institute (IVI)

The International Vaccine Institute (IVI) is a non-profit international organization established in 1997 on an initiative of the United Nations Development Program to discover, develop and provide safe, effective and affordable vaccines for global health. Our mission is to do so.

IVI's current portfolio includes preclinical treatments for infectious diseases that have a significant impact on low- and middle-income countries, including cholera, typhoid, chikungunya, rubella, salmonella, schistosomiasis, hepatitis E, HPV, and COVID-19. Includes vaccines at all stages of development and clinical development. 19, Others. IVI has developed the world's first low-cost oral cholera vaccine to be prequalified by the World Health Organization (WHO) and is also developing a new generation typhoid conjugate vaccine to receive WHO prequalification in early 2024. did.

IVI is headquartered in Seoul, South Korea, with a European regional office in Sweden, an African regional office in Rwanda, a country office in Austria, and a country and project office in Kenya. IVI also co-founded the Hong Kong Jockey Club Global Health Institute in Hong Kong and hosts collaborative centers in Ghana, Ethiopia and Madagascar. IVI has 39 member countries and the WHO, with national funding provided by the governments of South Korea, Sweden, India, Finland, and Thailand. For more information, please visit https://www.ivi.int.

agame Biological E. Limited

Biological E. Limited (BE), a Hyderabad-based pharmaceutical and biopharmaceutical company founded in 1953, is India's first private sector biopharmaceutical company and South India's first pharmaceutical company. BE develops, manufactures and supplies vaccines and therapeutics. BE supplies vaccines to more than 130 countries and its treatments are sold in India, the US and Europe. BE currently has eight WHO pre-qualified vaccines and ten USFDA-approved generic injectables in its portfolio. Recently, BE received Emergency Use Listing (EUL) from the WHO for its COVID-19 vaccine CORBEVAX®. Recently, the DCGI approved BE'S 14-valent pneumococcal conjugate vaccine.

In recent years, BE has embarked on new initiatives to expand its organization, including the development of special injections for the global market as a means to sustainably produce APIs, and the development of new vaccines for the global market.

Facebook, LinkedIn, and twitter

Media Contact


Aerie Em, Global Communications & Advocacy Manager
+82 2 881 1386 | aerie.em@ivi.int

Biological E. Limited

K. Vijay Amruth Raj
Email: Vijay.Kammari@biologicale.com

Source link